UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 380

Sortiert nach

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Trends in immunology, 2019-04, Vol.40 (4), p.328-344

2019

Link zum Volltext

Verfügbarkeit prüfen

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Journal of clinical oncology, 2016-12, Vol.34 (34), p.4102-4109

2016

Link zum Volltext

Verfügbarkeit prüfen

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB

PloS one, 2015-04, Vol.10 (4), p.e0123410-e0123410

2015

Link zum Volltext

Verfügbarkeit prüfen

Intralesional immunotherapy for melanoma

Journal of surgical oncology, 2014-03, Vol.109 (4), p.320-326

2014

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Pigment cell and melanoma research, 2015-05, Vol.28 (3), p.245-253

2015

Link zum Volltext

Verfügbarkeit prüfen

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma

Pigment cell and melanoma research, 2008-06, Vol.21 (3), p.358-367

2008

Link zum Volltext

Verfügbarkeit prüfen

Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

European journal of cancer (1990), 2022-02, Vol.162, p.241-242

Hersey, Peter

2022

Link zum Volltext

Verfügbarkeit prüfen

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

Journal of clinical oncology, 2013-05, Vol.31 (14), p.1767-1774

2013

Link zum Volltext

Verfügbarkeit prüfen

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients

Clinical cancer research, 2015-07, Vol.21 (14), p.3140-3148

2015

Link zum Volltext

Verfügbarkeit prüfen

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

Journal of clinical oncology, 2009-06, Vol.27 (17), p.2823-2830

2009

Link zum Volltext

Verfügbarkeit prüfen

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

Nature communications, 2018-08, Vol.9 (1), p.1-13, Article 3440

2018

Link zum Volltext

Verfügbarkeit prüfen

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers

Frontiers in genetics, 2021-06, Vol.12, p.680633-680633

2021

Link zum Volltext

Verfügbarkeit prüfen

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

Clinical cancer research, 2010-02, Vol.16 (3), p.1042-1048

2010

Link zum Volltext

Verfügbarkeit prüfen

MicroRNA-149, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma

Proceedings of the National Academy of Sciences - PNAS, 2011-09, Vol.108 (38), p.15840-15845

2011

Link zum Volltext

Verfügbarkeit prüfen

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

Journal of clinical oncology, 2006-10, Vol.24 (29), p.4738-4745

2006

Link zum Volltext

Verfügbarkeit prüfen

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma

Neoplasia (New York, N.Y.), 2016-02, Vol.18 (2), p.121-132

2016

Link zum Volltext

Verfügbarkeit prüfen

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

Clinical cancer research, 2012-02, Vol.18 (3), p.783-795

2012

Link zum Volltext

Verfügbarkeit prüfen

Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

Clinical cancer research, 2007-08, Vol.13 (16), p.4934-4942

2007

Link zum Volltext

Verfügbarkeit prüfen

Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress

Journal of investigative dermatology, 2014-02, Vol.134 (2), p.488-497

2014

Link zum Volltext

Verfügbarkeit prüfen

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways

Cancers, 2021-08, Vol.13 (17), p.4250

2021

Link zum Volltext

Verfügbarkeit prüfen

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

Journal of investigative dermatology, 2014-11, Vol.134 (11), p.2795-2805

2014

Link zum Volltext

Verfügbarkeit prüfen

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells

Cancers, 2022-01, Vol.14 (2), p.323

2022

Link zum Volltext

Verfügbarkeit prüfen

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

Molecular oncology, 2014-05, Vol.8 (3), p.544-554

2014

Link zum Volltext

Verfügbarkeit prüfen

New Challenges in Endpoints for Drug Development in Advanced Melanoma

Clinical cancer research, 2012-01, Vol.18 (2), p.336-341

2012

Link zum Volltext

Verfügbarkeit prüfen

Chemoablation of metastatic melanoma using intralesional Rose Bengal

Melanoma research, 2008-12, Vol.18 (6), p.405-411

2008

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 380

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(360)
Mit Volltextzugriff
(350)

Publikationsform

Sprache

Englisch
(379)
Japanisch
(54)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy

Programmed Death-Ligand 1 Expression and Response to the Anti-Programmed Death 1 Antibody Pembrolizumab in Melanoma

Inducible but not constitutive expression of PD-L1 in human melanoma cells is dependent on activation of NF-κB

Intralesional immunotherapy for melanoma

PD-L1 expression in melanoma shows marked heterogeneity within and between patients: implications for anti-PD-1/PD-L1 clinical trials

Adaptation to ER stress as a driver of malignancy and resistance to therapy in human melanoma

Re: Pyrexia in patients treated with dabrafenib plus trametinib across clinical trials in BRAF-mutant cancers

Pharmacodynamic Effects and Mechanisms of Resistance to Vemurafenib in Patients With Metastatic Melanoma

PD-L1 Expression and Tumor-Infiltrating Lymphocytes Define Different Subsets of MAPK Inhibitor-Treated Melanoma Patients

Results of a Phase III, Randomized, Placebo-Controlled Study of Sorafenib in Combination With Carboplatin and Paclitaxel As Second-Line Treatment in Patients With Unresectable Stage III or Stage IV Melanoma

SIRT6 haploinsufficiency induces BRAFV600E melanoma cell resistance to MAPK inhibitors via IGF signalling

Lysine Demethylases: Promising Drug Targets in Melanoma and Other Cancers

Phase II Trial of Tremelimumab (CP-675,206) in Patients with Advanced Refractory or Relapsed Melanoma

MicroRNA-149, a p53-responsive microRNA, functions as an oncogenic regulator in human melanoma

Bcl-2 Antisense (oblimersen sodium) Plus Dacarbazine in Patients With Advanced Melanoma: The Oblimersen Melanoma Study Group

Somatic Copy Number Amplification and Hyperactivating Somatic Mutations of EZH2 Correlate With DNA Methylation and Drive Epigenetic Silencing of Genes Involved in Tumor Suppression and Immune Responses in Melanoma

Modulation of NOXA and MCL-1 as a Strategy for Sensitizing Melanoma Cells to the BH3-Mimetic ABT-737

Apoptosis Induction in Human Melanoma Cells by Inhibition of MEK Is Caspase-Independent and Mediated by the Bcl-2 Family Members PUMA, Bim, and Mcl-1

Oncogenic Activation of MEK/ERK Primes Melanoma Cells for Adaptation to Endoplasmic Reticulum Stress

Transcriptional Reprogramming and Constitutive PD-L1 Expression in Melanoma Are Associated with Dedifferentiation and Activation of Interferon and Tumour Necrosis Factor Signalling Pathways

The Epigenetic Regulator I-BET151 Induces BIM-Dependent Apoptosis and Cell Cycle Arrest of Human Melanoma Cells

Nicotinamide Inhibits T Cell Exhaustion and Increases Differentiation of CD8 Effector T Cells

Differential activity of MEK and ERK inhibitors in BRAF inhibitor resistant melanoma

New Challenges in Endpoints for Drug Development in Advanced Melanoma

Chemoablation of metastatic melanoma using intralesional Rose Bengal

Suchergebnisse filtern